Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, ...
Too Old to Operate6d
Consensus on Treatment Goals for Generalized Pustular Psoriasis
The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...
Contract Pharma10h
Vanda & AnaptysBio Partner for the Development and Commercialization of Imsidolimab
Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.
AnaptysBio, Vanda announce exclusive global license agreement for Vanda
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Vanda, Anaptys Join on Development Pact
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and AnaptysBio, Inc. (Anaptys) (NASDAQ: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ...
National Institute for Health and Care Excellence4d
In consultation: Guidance and quality standards
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364] Draft guidance Technology appraisal guidance 18 February 2025 Spesolimab for treating generalised pustular psoriasis flares ...
rarediseaseadvisor6d
Treatment Goals and Outcome Measures for GPP Established by Global Consensus
A global Delphi panel of physicians and patients has achieved consensus on short- and long-term treatment goals and specific outcome measures for patients with generalized pustular psoriasis (GPP), ...